By
Jay Achar et al.
Published: Sept. 5, 2017, 8:26 p.m.·
Tags:
Drug-resistant TB,
Treatment,
Pediatrics
Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Read More →
